Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

C. C A M Peeters; H. C. Rümke; L. C. Sundermann; E. M. Rouppe Van Der Voort; J. Meulenbelt; M. Schuller; A. J. Kuipers; P. Van Der Ley; J. T. Poolman

doi:10.1016/0264-410X(96)00001-1

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

C. C A M Peeters
, H. C. Rümke
, L. C. Sundermann
, E. M. Rouppe Van Der Voort
, J. Meulenbelt
, M. Schuller
, A. J. Kuipers
, P. Van Der Ley
, J. T. Poolman^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

110 Citations (Scopus)

Abstract

A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer membrane proteins or PorA. The resulting hexavalent PorA OMV vaccine contained the serosubtypes P1.7,16; P1.5,2; P1.19,15; P1.7(h),4; P1.5(c),10; P1.12,13 and were used to immunize adult volunteers. A single immunization with two dosages, 7.5 and 15 μg of the individual PorAs, was studied The vaccine was considered safe for further use. Approximately half of the volunteers demonstrated a fourfold increase in bactericidal antibody activity against six test strains expressing the specific PorAs when given the higher dosage. This bactericidal activity was found to be directed against PorA.

Original language	English
Pages (from-to)	1009-1015
Number of pages	7
Journal	Vaccine
Volume	14
Issue number	10
DOIs	https://doi.org/10.1016/0264-410X(96)00001-1
Publication status	Published - 1 Jul 1996

Keywords

Meningococcal vaccine
Outer membrane vesicle
PorA

Access to Document

10.1016/0264-410X(96)00001-1

Cite this

@article{d941d7463a7f467d97c883637ff46cd8,

title = "Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine",

abstract = "A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer membrane proteins or PorA. The resulting hexavalent PorA OMV vaccine contained the serosubtypes P1.7,16; P1.5,2; P1.19,15; P1.7(h),4; P1.5(c),10; P1.12,13 and were used to immunize adult volunteers. A single immunization with two dosages, 7.5 and 15 μg of the individual PorAs, was studied The vaccine was considered safe for further use. Approximately half of the volunteers demonstrated a fourfold increase in bactericidal antibody activity against six test strains expressing the specific PorAs when given the higher dosage. This bactericidal activity was found to be directed against PorA.",

keywords = "Meningococcal vaccine, Outer membrane vesicle, PorA",

author = "Peeters, \{C. C A M\} and R{\"u}mke, \{H. C.\} and Sundermann, \{L. C.\} and \{Rouppe Van Der Voort\}, \{E. M.\} and J. Meulenbelt and M. Schuller and Kuipers, \{A. J.\} and \{Van Der Ley\}, P. and Poolman, \{J. T.\}",

year = "1996",

month = jul,

day = "1",

doi = "10.1016/0264-410X(96)00001-1",

language = "English",

volume = "14",

pages = "1009--1015",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

AU - Peeters, C. C A M

AU - Rümke, H. C.

AU - Sundermann, L. C.

AU - Rouppe Van Der Voort, E. M.

AU - Meulenbelt, J.

AU - Schuller, M.

AU - Kuipers, A. J.

AU - Van Der Ley, P.

AU - Poolman, J. T.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer membrane proteins or PorA. The resulting hexavalent PorA OMV vaccine contained the serosubtypes P1.7,16; P1.5,2; P1.19,15; P1.7(h),4; P1.5(c),10; P1.12,13 and were used to immunize adult volunteers. A single immunization with two dosages, 7.5 and 15 μg of the individual PorAs, was studied The vaccine was considered safe for further use. Approximately half of the volunteers demonstrated a fourfold increase in bactericidal antibody activity against six test strains expressing the specific PorAs when given the higher dosage. This bactericidal activity was found to be directed against PorA.

AB - A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer membrane proteins or PorA. The resulting hexavalent PorA OMV vaccine contained the serosubtypes P1.7,16; P1.5,2; P1.19,15; P1.7(h),4; P1.5(c),10; P1.12,13 and were used to immunize adult volunteers. A single immunization with two dosages, 7.5 and 15 μg of the individual PorAs, was studied The vaccine was considered safe for further use. Approximately half of the volunteers demonstrated a fourfold increase in bactericidal antibody activity against six test strains expressing the specific PorAs when given the higher dosage. This bactericidal activity was found to be directed against PorA.

KW - Meningococcal vaccine

KW - Outer membrane vesicle

KW - PorA

UR - https://www.scopus.com/pages/publications/0030197579

U2 - 10.1016/0264-410X(96)00001-1

DO - 10.1016/0264-410X(96)00001-1

M3 - Article

C2 - 8873396

AN - SCOPUS:0030197579

SN - 0264-410X

VL - 14

SP - 1009

EP - 1015

JO - Vaccine

JF - Vaccine

IS - 10

ER -

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this